Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Fmr LLC

Fmr LLC grew its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 0.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,314,014 shares of the company’s stock after buying an additional 21,133 shares during the quarter. Fmr LLC owned 0.15% of Krystal Biotech worth $675,833,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after acquiring an additional 28,707 shares during the period. State Street Corp increased its position in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the period. Geode Capital Management LLC increased its position in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after purchasing an additional 11,411 shares during the period. Franklin Resources Inc. raised its stake in shares of Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after buying an additional 62,178 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company’s stock valued at $38,095,000 after buying an additional 2,954 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on KRYS. Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Finally, Chardan Capital lifted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and a consensus price target of $220.00.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Price Performance

KRYS stock opened at $158.69 on Wednesday. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34. The firm has a market capitalization of $4.57 billion, a PE ratio of 53.07 and a beta of 0.75. The company’s 50 day simple moving average is $173.44 and its 200-day simple moving average is $172.60.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same quarter in the prior year, the firm earned $0.30 EPS. Krystal Biotech’s quarterly revenue was up 116.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).